Mikhail Kosiborod, MD
Enriched profileVice President of Research, Saint Luke's Health System · Saint Luke's Mid America Heart Institute
Mikhail Kosiborod is Vice President of Research, Saint Luke's Health System at Saint Luke's Mid America Heart Institute. OpenAlex indexes 880 publications with 71,275 citations (h-index 118); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 21 Oct 2026
Mikhail Kosiborod, MD, is Vice President of Research, Saint Luke's Health System at Saint Luke's Mid America Heart Institute. The public record shows 880 publications with 71,275 citations (h-index 118), centered on Diabetes Treatment and Management, Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 26 companies.
- Most recent indexed publication: 2026 · Circulation. Population health and outcomes
- Top research focus: Diabetes Treatment and Management
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 26 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 73 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 436.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Sponsor: Matthew Neal MD
- Dapagliflozin in Respiratory Failure in Patients With COVID-19
Sponsor: Saint Luke's Health System
- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Sponsor: Saint Luke's Health System
Industry payments
Updated 21 Oct 2026
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Boehringer Ingelheim International GmbHProgram year202418 payments$40,196openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202428 payments$30,826openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.6%GLP-1 receptor agonist20.5%Ozempic63%Mounjaro29%Trulicity8%Part D≥108 patientsThiazolidinedione11.5%Pioglitazone Hcl100%Part D≥109 patients+ 6 more classes in this area
Cardiovascular
46.4%Statin14.6%Rosuvastatin Calcium59%Atorvastatin Calcium35%Pravastatin Sodium6%Part D<11 patientsCholesterol absorption inhibitor8.7%Ezetimibe100%Part D≥76 patients+ 10 more classes in this area
Blood & clotting
3%Factor Xa inhibitor1.6%Eliquis100%Part D≥14 patientsP2Y12 inhibitor1.4%Clopidogrel100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 21 Oct 2026
27 congress contributions (2018–2024) across ADA, ENDO per OpenAlex. The most recent:
- 1937-LB: Coordinated Approach to Improve Quality of Care and Address Disparities in Patients with Cardiometabolic Disease—Analysis from the Cardiometabolic Center Alliance Registry
ADA Scientific Sessions
ADA2024Presenting authorLate-breaking - 1077-P: A Multicenter Initiative to Improve Care in Cardiometabolic Disease—Initial Report From Cardiometabolic Center Alliance (CMCA)
ADA Scientific Sessions
ADA2023Presenting authorPoster - 1167-P: Burden of Cardiorenal Complications (CRCs) in T2D: Take Care of Me Programme
ADA Scientific Sessions
ADA2022Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.
Circulation. Population health and outcomes
Article2026 - Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide.
European heart journal
Article2025
Most-cited works
by citation count (OpenAlex)- 01Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionArticle7,108 citations2019
- 02
- 03Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionArticle2,858 citations2022
- 04Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart AssociationArticle2,152 citations2023
- 05
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mikhail-kosiborod-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cardiometabolichealth.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Diabetes Committee, American Heart Association
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗ - Inaugural holder
Ben McCallister, MD Endowed Chair in Cardiovascular Research, Saint Luke's Health System
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →saintlukeskc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
University of Missouri-Kansas City School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cardiometabolichealth.org ↗ - Director of Cardiometabolic Research
Saint Luke's Michael and Marlys Haverty Cardiometabolic Center of Excellence
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cardiometabolichealth.org ↗ - Executive Director
Cardiometabolic Center Alliance
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →saintlukeskc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →saintlukeskc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →spreaker.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)